Full-Time

Group Leader

Drug Product Analytics

Posted on 4/2/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$150k - $174kAnnually

Senior, Expert

San Carlos, CA, USA

Position requires onsite presence in San Carlos, CA.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • MSc in Pharmaceutics, Chemistry, Biophysics or Biochemistry preferred, with >10 years of industrial experience; or PhD in Pharmaceutics, Chemistry, Biophysics or Biochemistry with > 5 years of relevant experience.
  • The candidate will have had strong experience in characterization of Biological Drug Products containing proteins, polysaccharides and/or protein conjugate formulations. Experience in characterization of vaccine systems containing adjuvants will be an advantage.
  • Experience of testing within GxP environments either directly or through CMOs.
  • Strong experience in method development for HPLC (SEC, RP, AEX, HPAEC-PAD) based assays, particle light scattering analysis (DLS, MALS), quantitative subvisible particle analysis (MFI, Laser Diffraction), visible analysis, is required.
  • Demonstrated experience in authoring analytical technical documents, including method protocols and SOPs, assay transfer and implementation protocols and reports, validation protocols and reports.
  • Participated in method transfers to external vendors and to internal collaborators.
  • Strong scientific leadership is required: critical thinking, ability to present complex data sets and to independently propose and design follow-up experiments.
  • Managerial experience is of notable benefit.
  • The candidate should have high degrees of both flexibility and organizational skills as well as an eagerness and ability to learn to effectively navigate Vaxcyte’s multiple projects and timelines.
  • Strong interpersonal skills, ability to communicate effectively both verbally and in written formats are necessary to collaborate effectively with the rest of the Drug Product Development team and well as across other teams.
  • Detail oriented, rigorous and excellent skills in record keeping.
Responsibilities
  • Leading analytical method development and execution for Drug Product characterization.
  • Lead (direct management) a team of scientists to support process development activities, formulation selection and stability analysis of Drug Product and/or Intermediate and Drug Substance materials.
  • Evaluate and develop the most appropriate biochemical and biophysical characterization tools to support biological drug product development, including adjuvanted vaccine drug products.
  • Apply biophysical characterization techniques to fully understand antigen/adjuvant interactions and to assess formulation matrix optimization options.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. Unlike traditional cell-based methods, their approach allows for the development of broad-spectrum vaccines. Vaxcyte's goal is to provide effective vaccines that can significantly reduce the impact of bacterial diseases on global health.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

2%

1 year growth

2%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA Breakthrough Therapy designation for VAX-24 may accelerate its market entry.
  • Global pneumococcal vaccines market is projected to grow at a CAGR of 5.6% until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA technology developers like Moderna and BioNTech is intense.
  • Potential regulatory delays could impact Vaxcyte's clinical trial timelines.
  • Intellectual property disputes may arise over cell-free protein synthesis technology.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae bacteria.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections, unlike traditional methods.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

INACTIVE